Zou Xing-Li, Liu Ting, Meng Wen-Tong, Huang Xiao-Ou
Department of Hematology, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Oct;16(5):1086-90.
To study the expression and significance of pten gene in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), RT-PCR and Western blot were respectively applied to detect pten mRNA and PTEN protein in Jurkat cells (as negative control), in bone marrow nucleated cells of 35 patients with MDS, 45 patients with AML and 20 normal control. The results showed that pten mRNA expression could not be detected in Jurkat cells, and the positive rate in MDS patients (77.1%) was significantly lower than that in normal control group (90.0%) (p > 0.05), while significant difference was found between AML patients and normal control (60.0% vs 90.0%, p < 0.05); the positive rate in MDS-RAEB patients (70.0%) was lower than that in MDS-RCMD (86.7%); positive rate in de novo and relapsed AML patients (53.3%) was lower than that in AML patients in CR (73.3%), but statistics tests did not show significant difference (p > 0.05). The results of relative expression level of pten mRNA in all groups indicated that both relative expression levels in MDS patients and AML patients were definitely lower than that in normal control group (p < 0.005); the relative expression level in MDS-RAEB patients was lower than that in MDS-RCMD patients (p < 0.05); and in de novo and relapsed AML patients was obviously lower than that in AML patients in CR (p < 0.001). However, there was no significant difference between MDS and AML patients (p > 0.05). The positive rate of PTEN protein expression in both MDS (65.7%) and AML (54.8%) patients were lower than that in normal control (90.0%) (p < 0.05), and there was no significant difference when comparing MDS-RCMD patients (80.0%) with MDS-RAEB patients (55.0%) (p > 0.05), but positive rate of PTEN protein expression in de novo and relapsed AML patients (44.4%) was significantly lower than that in AML patients in CR (73.3%) (p < 0.05). It is concluded that the complete loss of pten mRNA in MDS and AML is uncommon, but the relative expression level in both diseases is significantly lower than that in normal people. The positive rates of PTEN protein expression in both MDS and AML patients are lower, compared with normal people, but are not in accordance with the expression of pten mRNA. The abnormalities of pten gene expression may be involved in the pathogenesis of MDS and AML.
为研究抑癌基因（pten）在骨髓增生异常综合征（MDS）和急性髓系白血病（AML）患者中的表达及意义，分别采用逆转录-聚合酶链反应（RT-PCR）和蛋白质免疫印迹法（Western blot）检测Jurkat细胞（作为阴性对照）、35例MDS患者、45例AML患者及20例正常对照者骨髓有核细胞中pten mRNA及PTEN蛋白的表达。结果显示，Jurkat细胞中未检测到pten mRNA表达，MDS患者的阳性率（77.1%）显著低于正常对照组（90.0%）（p>0.05），AML患者与正常对照组之间差异有统计学意义（60.0%比90.0%，p<0.05）；MDS-RAEB患者的阳性率（70.0%）低于MDS-RCMD患者（86.7%）；初发及复发AML患者的阳性率（53.3%）低于完全缓解（CR）的AML患者（73.3%），但差异无统计学意义（p>0.05）。各组pten mRNA相对表达水平结果显示，MDS患者和AML患者的相对表达水平均明显低于正常对照组（p<0.005）；MDS-RAEB患者的相对表达水平低于MDS-RCMD患者（p<0.05）；初发及复发AML患者的相对表达水平明显低于CR的AML患者（p<0.001）。然而，MDS患者与AML患者之间差异无统计学意义（p>0.05）。MDS患者（65.7%）和AML患者（54.8%）PTEN蛋白表达阳性率均低于正常对照组（90.0%）（p<0.05），MDS-RCMD患者（80.0%）与MDS-RAEB患者（55.0%）比较差异无统计学意义（p>0.05），但初发及复发AML患者PTEN蛋白表达阳性率（44.4%）明显低于CR的AML患者（73.3%）（p<0.05）。结论：MDS和AML患者pten mRNA完全缺失少见，但两种疾病的相对表达水平均显著低于正常人。MDS和AML患者PTEN蛋白表达阳性率均低于正常人，但与pten mRNA表达不一致。pten基因表达异常可能参与MDS和AML的发病机制。
